ESN Cleer is focused on repurposing existing drugs to develop treatments for orphan cardiomyopathies, which currently lack guideline-recommended therapies. These rare diseases significantly contribute to heart failure and severely impact patients' quality of life, highlighting the urgent need for effective medical solutions.
Funding
$3.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Orphan cardiomyopathies lack specific drug treatments, contributing significantly to heart failure and severely impacting patients' quality of life. The absence of guideline-recommended therapies for these rare diseases creates an urgent need for effective medical solutions.
Solution
ESN Cleer focuses on repurposing existing drugs to develop treatments for orphan cardiomyopathies. By identifying and reformulating already-approved compounds, ESN Cleer aims to accelerate the availability of therapies for these rare cardiac conditions. This approach potentially reduces development time and cost compared to developing novel drugs, offering a faster path to addressing unmet medical needs in specific segments of cardiomyopathy. The company's efforts are directed towards mitigating the high mortality risk and improving the quality of life for individuals affected by these diseases.
Target Audience
The primary target audience includes patients suffering from orphan cardiomyopathies, as well as healthcare providers and medical professionals seeking treatment options for these conditions.
Features
- Focus on repurposing existing drugs to treat orphan cardiomyopathies.
- Aims to provide treatments for rare diseases without specific drug treatments.
- Targets specific segments of cardiomyopathy to combat heart failure.